CleoDX

Cleo Diagnostics is bringing to market a simple blood test for the accurate and early diagnosis of ovarian cancer
Screenshot 2024-04-05 at 12.42.00 pm.png

Introducing Cleo Diagnostics

Watch the video to learn how we are making earlier detection of ovarian cancer a reality

Latest News

News
The Royal Women's Hospital Melbourne Joins CLEO Ovarian Cancer Trial
The Royal Women's Hospital Melbourne Joins CLEO Ovarian Cancer Trial

CLEO has expanded its ovarian cancer Australian trial with the inclusion of the Royal Women’s Hospital as a participating site.

Read More →
Cleo Commences U.S. Clinical Trials
Cleo Commences U.S. Clinical Trials

Ovarian cancer diagnostics company, Cleo Diagnostics Limited (ASX:COV) is pleased to confirm the commencement of U.S. clinical trials for its ovarian cancer diagnostic blood test.

Read More →
CLEO Selects U.S. Clinical Trial Sites
CLEO Selects U.S. Clinical Trial Sites

Cleo Diagnostics Limited (ASX:COV) is pleased to announce progress for its U.S. clinical trials in support of its FDA application for its ovarian cancer diagnostic blood test.

Read More →

Latest Announcements

Featured
The Royal Women's Hospital Melbourne Joins CLEO Ovarian Cancer Trial
Cleo Commences U.S. Clinical Trials
CLEO Selects U.S. Clinical Trial Sites

See All >

Share Price

Latest Reports

Featured
June 2024 Quarterly Activities Report
March 2024 Quarterly Activities Report

See All >